Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy

Clinical course and patient follow-up

Julie Marie Vose, Philip Jay Bierman, James R. Anderson, Anne Kessinger, Jene Pierson, Jean Nelson, Bettina Frappier, Kim Schmit-Pokorny, Dennis D. Weisenburger, James Olen Armitage

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Of 364 patients with lymphoid malignancy who underwent high-dose therapy with autologous bone marrow transplantation (ABMT) or peripheral stem cell transplantation (PSCT), 169 patients have had progressive disease after the procedure. The median survival from the time of relapse for patients with Hodgkin's disease (HD) who progressed after the transplant was 10.5 months. This compares with a median survival of 3 months for relapsed non-Hodgkin's lymphoma (NHL) patients (P = .0036). After failing transplantation, 56 patients were treated with further chemotherapy 35 with involved field irradiation therapy, and 18 patients were treated with combination chemotherapy and irradiation. Seven patients received biologic therapy and seven patients underwent a second bone marrow transplant. The remainder of the patients were believed to be too ill for further therapy or chose not to receive further treatment for their recurrent lymphoid malignancy. Sixty of the 169 patients with progressive disease after the transplant are still alive; however, only 18 patients are alive off therapy without evidence of active disease after their relapse. Ten of the 18 patients are still less than 12 months past their posttransplant salvage therapy and are at high-risk for relapse. Five patients are progression free at 15 to 36 months after their posttransplant relapse. Only three patients (two NHL and one HD) treated with other modalities after autologous transplant failure are alive without evidence of disease and have been observed at least 4 years postrelapse. Although a few patients will have a durable response to subsequent therapy, the majority of patients who have progressive disease after an autologous transplant for lymphoid malignancy will succumb to recurrent disease within a short period of time.

Original languageEnglish (US)
Pages (from-to)2142-2148
Number of pages7
JournalBlood
Volume80
Issue number8
StatePublished - Oct 15 1992

Fingerprint

Autologous Transplantation
Transplants
Neoplasms
Chemotherapy
Autografts
Therapeutics
Bone
Irradiation
Recurrence
Salvaging
Stem cells
Hodgkin Disease
Non-Hodgkin's Lymphoma
Peripheral Blood Stem Cell Transplantation
Salvage Therapy
Biological Therapy
Survival
Combination Drug Therapy
Bone Marrow Transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy : Clinical course and patient follow-up. / Vose, Julie Marie; Bierman, Philip Jay; Anderson, James R.; Kessinger, Anne; Pierson, Jene; Nelson, Jean; Frappier, Bettina; Schmit-Pokorny, Kim; Weisenburger, Dennis D.; Armitage, James Olen.

In: Blood, Vol. 80, No. 8, 15.10.1992, p. 2142-2148.

Research output: Contribution to journalArticle

Vose, JM, Bierman, PJ, Anderson, JR, Kessinger, A, Pierson, J, Nelson, J, Frappier, B, Schmit-Pokorny, K, Weisenburger, DD & Armitage, JO 1992, 'Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up', Blood, vol. 80, no. 8, pp. 2142-2148.
Vose, Julie Marie ; Bierman, Philip Jay ; Anderson, James R. ; Kessinger, Anne ; Pierson, Jene ; Nelson, Jean ; Frappier, Bettina ; Schmit-Pokorny, Kim ; Weisenburger, Dennis D. ; Armitage, James Olen. / Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy : Clinical course and patient follow-up. In: Blood. 1992 ; Vol. 80, No. 8. pp. 2142-2148.
@article{675a1d5cd8854fd89b314b40851fa45f,
title = "Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up",
abstract = "Of 364 patients with lymphoid malignancy who underwent high-dose therapy with autologous bone marrow transplantation (ABMT) or peripheral stem cell transplantation (PSCT), 169 patients have had progressive disease after the procedure. The median survival from the time of relapse for patients with Hodgkin's disease (HD) who progressed after the transplant was 10.5 months. This compares with a median survival of 3 months for relapsed non-Hodgkin's lymphoma (NHL) patients (P = .0036). After failing transplantation, 56 patients were treated with further chemotherapy 35 with involved field irradiation therapy, and 18 patients were treated with combination chemotherapy and irradiation. Seven patients received biologic therapy and seven patients underwent a second bone marrow transplant. The remainder of the patients were believed to be too ill for further therapy or chose not to receive further treatment for their recurrent lymphoid malignancy. Sixty of the 169 patients with progressive disease after the transplant are still alive; however, only 18 patients are alive off therapy without evidence of active disease after their relapse. Ten of the 18 patients are still less than 12 months past their posttransplant salvage therapy and are at high-risk for relapse. Five patients are progression free at 15 to 36 months after their posttransplant relapse. Only three patients (two NHL and one HD) treated with other modalities after autologous transplant failure are alive without evidence of disease and have been observed at least 4 years postrelapse. Although a few patients will have a durable response to subsequent therapy, the majority of patients who have progressive disease after an autologous transplant for lymphoid malignancy will succumb to recurrent disease within a short period of time.",
author = "Vose, {Julie Marie} and Bierman, {Philip Jay} and Anderson, {James R.} and Anne Kessinger and Jene Pierson and Jean Nelson and Bettina Frappier and Kim Schmit-Pokorny and Weisenburger, {Dennis D.} and Armitage, {James Olen}",
year = "1992",
month = "10",
day = "15",
language = "English (US)",
volume = "80",
pages = "2142--2148",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy

T2 - Clinical course and patient follow-up

AU - Vose, Julie Marie

AU - Bierman, Philip Jay

AU - Anderson, James R.

AU - Kessinger, Anne

AU - Pierson, Jene

AU - Nelson, Jean

AU - Frappier, Bettina

AU - Schmit-Pokorny, Kim

AU - Weisenburger, Dennis D.

AU - Armitage, James Olen

PY - 1992/10/15

Y1 - 1992/10/15

N2 - Of 364 patients with lymphoid malignancy who underwent high-dose therapy with autologous bone marrow transplantation (ABMT) or peripheral stem cell transplantation (PSCT), 169 patients have had progressive disease after the procedure. The median survival from the time of relapse for patients with Hodgkin's disease (HD) who progressed after the transplant was 10.5 months. This compares with a median survival of 3 months for relapsed non-Hodgkin's lymphoma (NHL) patients (P = .0036). After failing transplantation, 56 patients were treated with further chemotherapy 35 with involved field irradiation therapy, and 18 patients were treated with combination chemotherapy and irradiation. Seven patients received biologic therapy and seven patients underwent a second bone marrow transplant. The remainder of the patients were believed to be too ill for further therapy or chose not to receive further treatment for their recurrent lymphoid malignancy. Sixty of the 169 patients with progressive disease after the transplant are still alive; however, only 18 patients are alive off therapy without evidence of active disease after their relapse. Ten of the 18 patients are still less than 12 months past their posttransplant salvage therapy and are at high-risk for relapse. Five patients are progression free at 15 to 36 months after their posttransplant relapse. Only three patients (two NHL and one HD) treated with other modalities after autologous transplant failure are alive without evidence of disease and have been observed at least 4 years postrelapse. Although a few patients will have a durable response to subsequent therapy, the majority of patients who have progressive disease after an autologous transplant for lymphoid malignancy will succumb to recurrent disease within a short period of time.

AB - Of 364 patients with lymphoid malignancy who underwent high-dose therapy with autologous bone marrow transplantation (ABMT) or peripheral stem cell transplantation (PSCT), 169 patients have had progressive disease after the procedure. The median survival from the time of relapse for patients with Hodgkin's disease (HD) who progressed after the transplant was 10.5 months. This compares with a median survival of 3 months for relapsed non-Hodgkin's lymphoma (NHL) patients (P = .0036). After failing transplantation, 56 patients were treated with further chemotherapy 35 with involved field irradiation therapy, and 18 patients were treated with combination chemotherapy and irradiation. Seven patients received biologic therapy and seven patients underwent a second bone marrow transplant. The remainder of the patients were believed to be too ill for further therapy or chose not to receive further treatment for their recurrent lymphoid malignancy. Sixty of the 169 patients with progressive disease after the transplant are still alive; however, only 18 patients are alive off therapy without evidence of active disease after their relapse. Ten of the 18 patients are still less than 12 months past their posttransplant salvage therapy and are at high-risk for relapse. Five patients are progression free at 15 to 36 months after their posttransplant relapse. Only three patients (two NHL and one HD) treated with other modalities after autologous transplant failure are alive without evidence of disease and have been observed at least 4 years postrelapse. Although a few patients will have a durable response to subsequent therapy, the majority of patients who have progressive disease after an autologous transplant for lymphoid malignancy will succumb to recurrent disease within a short period of time.

UR - http://www.scopus.com/inward/record.url?scp=0026788310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026788310&partnerID=8YFLogxK

M3 - Article

VL - 80

SP - 2142

EP - 2148

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -